Zekavat Omid Reza, Shakibazad Nader, Dehghani Seyed Javad, Bordbar Mohammadreza, Haghpanah Sezaneh
Hematology Research Center, Shiraz University of Medical Sciences Shiraz, Iran.
Department of Pediatric Hematology and Oncology, Bushehr University of Medical Sciences Bushehr, Iran.
Am J Blood Res. 2025 Aug 15;15(4):80-89. doi: 10.62347/QFMM6731. eCollection 2025.
Glucose 6-phosphate dehydrogenase (G6PD) activity of red blood cells (RBC) may be helpful as a prognostic factor and a probable predictive indicator of disease activity in children with acute lymphoblastic leukemia (ALL).
This cross-sectional, case-control study was performed on almost 133 pediatric ALL cases from 2016 to 2020 in an oncology hospital. Patients with a history of blood transfusion within the last three months, acute hemolytic crisis, any other type of enzyme deficiency like pyruvate kinase and hexokinase, and chronic liver disease were excluded. The G6PD activity in RBC was measured using the spectrophotometric method. In addition, the G6PD activity was assessed in 133 normal individuals as a control group. According to the kit, the G6PD <1.5 IU/g of Hb level was recognized as severely deficient. The correlation of G6PD activity with disease activity and other parameters in ALL patients was determined using the Pearson correlation test. Data were measured by an independent t-test and a one-way ANOVA test.
The mean G6PD activity of RBC in the control (n=133) and patient group (n=128) was 9.1±2.08 IU/g of Hb and 11.12±3.8 IU/g of Hb, P<0.001, respectively. There was a significant difference in the G6PD activity of RBC in patients' blastic and non-blastic phases, t (128) =-2.48, P=0.014.
The G6PD activity of RBC is higher in childhood ALL than in the control group. Moreover, the G6PD activity of RBC in the blastic phase of leukemia was higher than that of patients in remission.
红细胞葡萄糖6磷酸脱氢酶（G6PD）活性可能有助于作为急性淋巴细胞白血病（ALL）患儿疾病活动的预后因素和可能的预测指标。
本横断面病例对照研究于2016年至2020年在一家肿瘤医院对近133例儿科ALL病例进行。排除过去三个月内有输血史、急性溶血危机、任何其他类型的酶缺乏（如丙酮酸激酶和己糖激酶）以及慢性肝病的患者。采用分光光度法测定红细胞中的G6PD活性。此外，对133名正常个体作为对照组进行G6PD活性评估。根据试剂盒，G6PD<1.5 IU/g血红蛋白水平被认定为严重缺乏。使用Pearson相关检验确定ALL患者中G6PD活性与疾病活动及其他参数的相关性。数据通过独立t检验和单因素方差分析进行测量。
对照组（n = 133）和患者组（n = 128）红细胞的平均G6PD活性分别为9.1±2.08 IU/g血红蛋白和11.12±3.8 IU/g血红蛋白，P<0.001。患者的原始期和非原始期红细胞G6PD活性存在显著差异，t（128）=-2.48，P = 0.014。
儿童ALL患者红细胞的G6PD活性高于对照组。此外，白血病原始期患者红细胞的G6PD活性高于缓解期患者。
